Phase IIa trial to evaluate two different doses of AQX 1125 in volunteers exposed to an environmental inflammatory stimulus

Trial Profile

Phase IIa trial to evaluate two different doses of AQX 1125 in volunteers exposed to an environmental inflammatory stimulus

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2013

At a glance

  • Drugs Rosiptor (Primary)
  • Indications Allergic asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Apr 2013 Primary endpoint 'Inflammatory-markers' has been met according to an Aquinox media release.
    • 15 Nov 2011 Planned End Date changed to 31 Dec 2012.
    • 14 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top